CDEK
← All drugs Report issue

tucotuzumab celmoleukin

mAbexperimentalADC

Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin). — Wikipedia

Clinical trial activity

3 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2000 (NCT00016237)

Timeline

2000s

  1. Jan 1, 2000

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • Epithelial cell adhesion moleculeINHIBITOR

    EPCAM inhibitor

  • Epithelial cell adhesion moleculeOTHER

    EPCAM other

    Immunomodulator. The humanized monoclonal antibody moiety of tucotuzumab celmoleukin recognizes and binds to EpCAM thereby concentrating IL2 (celmoleukin) in EpCAM-expressing tumor tissue. Subsequently, the localized IL2 moiety of this fusion protein may stimulate a cytotoxic T-cell antitumor immune response.

  • Disialoganglioside GD2OTHER

    Disialoganglioside GD2 other

    APN301 is designed to localize GD2-positive tumor cells via the antibody component. The fused IL2 then stimulates the patient's immune system against the tumor by activation of both, NK and T cells, whereas the Fc portion of the antibody is designed to trigger tumor cell killing by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No
Payload
IL2

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • emd-273063
  • emd273066
  • emd 273066
  • emd 273066
  • emd-273066
  • emd-273066
  • huks-il2
  • huks-il2
  • ksa-interleukin-2
  • tucotuzumab celmoleukin
  • tucotuzumab celmoleukin
  • tucotuzumab celmoleukin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00408967Phase 2Dec 1, 2006Merck KGaA, Merck Serono
NCT00132522Phase 1May 1, 2005Merck Serono, University of Wisconsin
NCT00016237Phase 1Dec 1, 2000Cornell University, Merck Serono, National Cancer Institute (NCI)
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Merck SeronoFor profit3322000
Cornell UniversityAcademic/Hospital1012000
Merck KGaAFor profit1012006
National Cancer Institute (NCI)Government1012000
University of WisconsinAcademic/Hospital1012005
5 organizations
Page 1 / 1